Anika Therapeutics Inc Financials
This page shows Anika Therapeutics Inc (ANIK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Anika Therapeutics Inc has an operating margin of -4.3%, meaning the company retains $-4 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from 0.7% the prior year.
Anika Therapeutics Inc's revenue declined 0.7% year-over-year, from $120.8M to $119.9M. This contraction results in a growth score of 26/100.
Anika Therapeutics Inc carries a low D/E ratio of 0.32, meaning only $0.32 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.88, Anika Therapeutics Inc holds $4.88 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Anika Therapeutics Inc generated $5.4M in operating cash flow, capex of $7.7M consumed most of it, leaving -$2.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Anika Therapeutics Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Anika Therapeutics Inc generates $-0.10 in operating cash flow ($5.4M OCF vs -$56.4M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Key Financial Metrics
Anika Therapeutics Inc generated $119.9M in revenue in fiscal year 2024. This represents a decrease of 0.7% from the prior year.
Anika Therapeutics Inc's EBITDA was $1.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 75.5% from the prior year.
Anika Therapeutics Inc generated -$2.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 67.7% from the prior year.
Anika Therapeutics Inc reported -$56.4M in net income in fiscal year 2024. This represents an increase of 31.8% from the prior year.
Anika Therapeutics Inc earned $-3.83 per diluted share (EPS) in fiscal year 2024. This represents an increase of 32.1% from the prior year.
Anika Therapeutics Inc held $55.6M in cash against $0 in long-term debt as of fiscal year 2024.
Anika Therapeutics Inc had 14M shares outstanding in fiscal year 2024. This represents a decrease of 1.7% from the prior year.
Anika Therapeutics Inc's gross margin was 63.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 4.9 percentage points from the prior year.
Anika Therapeutics Inc's operating margin was -4.3% in fiscal year 2024, reflecting core business profitability. This is down 5.0 percentage points from the prior year.
Anika Therapeutics Inc's net profit margin was -47.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 21.4 percentage points from the prior year.
Anika Therapeutics Inc invested $25.5M in research and development in fiscal year 2024. This represents an increase of 17.4% from the prior year.
Anika Therapeutics Inc spent $10.9M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents an increase of 118.3% from the prior year.
Anika Therapeutics Inc invested $7.7M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 42.5% from the prior year.
ANIK Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.8M-1.4% | $28.2M+7.8% | $26.2M-14.5% | $30.6M-0.4% | $30.7M+5.9% | $29.0M+1101.1% | -$2.9M-107.0% | $41.5M |
| Cost of Revenue | $12.2M-11.7% | $13.9M+20.6% | $11.5M-14.8% | $13.5M+31.7% | $10.2M+1.9% | $10.0M+215.9% | -$8.7M-152.5% | $16.5M |
| Gross Profit | $15.6M+8.5% | $14.4M-2.2% | $14.7M-14.3% | $17.1M-16.4% | $20.5M+8.0% | $19.0M+228.7% | $5.8M-76.9% | $24.9M |
| R&D Expenses | $6.9M+10.0% | $6.3M+4.2% | $6.1M-6.9% | $6.5M-2.6% | $6.7M+4.3% | $6.4M+291.8% | -$3.3M-142.9% | $7.8M |
| SG&A Expenses | $11.9M-2.9% | $12.2M-5.2% | $12.9M+14.0% | $11.3M-27.5% | $15.6M+3.6% | $15.1M+196.7% | -$15.6M-162.8% | $24.8M |
| Operating Income | -$3.2M+22.7% | -$4.2M+2.4% | -$4.3M-507.7% | -$705K+61.0% | -$1.8M+27.7% | -$2.5M-110.1% | $24.7M+421.9% | -$7.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $939K+37.9% | $681K+665.2% | $89K-96.5% | $2.5M+90.4% | $1.3M+2983.7% | $43K-99.5% | $9.1M+2054.9% | -$463K |
| Net Income | -$2.3M+41.3% | -$4.0M+18.5% | -$4.9M+77.7% | -$21.9M-24746.6% | -$88K+98.1% | -$4.5M+92.8% | -$63.0M-858.0% | -$6.6M |
| EPS (Diluted) | $-0.16+42.9% | $-0.28+17.6% | $-0.34+77.2% | $-1.49 | $0.00+100.0% | $-0.31+92.8% | $-4.29-853.3% | $-0.45 |
ANIK Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $189.4M+0.9% | $187.7M-1.5% | $190.6M-6.0% | $202.7M-22.8% | $262.7M-0.4% | $263.7M-2.5% | $270.6M-17.5% | $328.2M |
| Current Assets | $101.6M+2.3% | $99.3M-3.1% | $102.5M-9.8% | $113.7M-26.7% | $155.0M-2.5% | $159.0M-2.7% | $163.3M+4.2% | $156.8M |
| Cash & Equivalents | $58.0M+9.1% | $53.2M-0.4% | $53.4M-4.1% | $55.6M-11.4% | $62.8M-8.5% | $68.6M-0.2% | $68.7M-2.7% | $70.7M |
| Inventory | $16.3M-3.8% | $16.9M-20.7% | $21.3M-10.4% | $23.8M-53.7% | $51.5M+4.2% | $49.4M+102.3% | $24.4M-44.1% | $43.7M |
| Accounts Receivable | $22.2M-7.4% | $24.0M+9.0% | $22.0M-6.8% | $23.6M-30.1% | $33.8M+5.3% | $32.1M+21.7% | $26.4M-24.0% | $34.7M |
| Goodwill | $8.1M-0.1% | $8.1M+8.5% | $7.4M+4.2% | $7.1M-3.1% | $7.3M-0.7% | $7.4M-2.2% | $7.6M+4.4% | $7.3M |
| Total Liabilities | $42.6M+6.6% | $40.0M-5.2% | $42.2M-13.4% | $48.8M-6.8% | $52.3M-5.2% | $55.2M-5.4% | $58.4M+1.2% | $57.7M |
| Current Liabilities | $19.1M+18.7% | $16.1M-10.2% | $17.9M-23.2% | $23.3M-10.8% | $26.1M-8.2% | $28.5M-8.4% | $31.1M+10.7% | $28.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $146.8M-0.6% | $147.7M-0.5% | $148.4M-3.6% | $154.0M-26.8% | $210.3M+0.9% | $208.5M-1.8% | $212.3M-21.5% | $270.5M |
| Retained Earnings | $60.5M-3.7% | $62.8M-5.9% | $66.8M-6.8% | $71.7M-41.9% | $123.5M-0.1% | $123.5M-3.5% | $128.1M-33.0% | $191.1M |
ANIK Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6.9M+3734.9% | -$189K-45.4% | -$130K-108.2% | $1.6M+248.0% | -$1.1M-748.4% | -$126K-103.5% | $3.6M-43.9% | $6.5M |
| Capital Expenditures | $1.9M+28.6% | $1.5M-48.1% | $2.8M+116.1% | $1.3M-61.6% | $3.4M+88.2% | $1.8M-1.7% | $1.8M+148.3% | $741K |
| Free Cash Flow | $5.0M+400.9% | -$1.7M+43.9% | -$3.0M-1174.2% | $275K+106.1% | -$4.5M-131.2% | -$1.9M-207.6% | $1.8M-68.7% | $5.7M |
| Investing Cash Flow | -$1.7M-221.3% | -$539K-132.2% | $1.7M+227.9% | -$1.3M+61.6% | -$3.4M-88.2% | -$1.8M+1.7% | -$1.8M-148.3% | -$741K |
| Financing Cash Flow | -$13K-107.3% | $179K+103.3% | -$5.4M-1.6% | -$5.4M-381.9% | -$1.1M+51.1% | -$2.3M-764.6% | $342K+410.9% | -$110K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0 | $0-100.0% | $4.0M-28.8% | $5.6M+306.9% | $1.4M | $0 | $0 | $0 |
ANIK Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.0%+5.1pp | 50.9%-5.2pp | 56.1%+0.1pp | 56.0%-10.7pp | 66.7%+1.3pp | 65.4% | N/A | 60.2% |
| Operating Margin | -11.6%+3.2pp | -14.8%+1.6pp | -16.4%-14.1pp | -2.3%+3.6pp | -5.9%+2.7pp | -8.6% | N/A | -18.5% |
| Net Margin | -8.4%+5.7pp | -14.1%+4.6pp | -18.6%+52.8pp | -71.5%-71.2pp | -0.3%+15.3pp | -15.6% | N/A | -15.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -1.2%+0.9pp | -2.1%+0.4pp | -2.6%+8.2pp | -10.8%-10.8pp | -0.0%+1.7pp | -1.7%+21.6pp | -23.3%-21.3pp | -2.0% |
| Current Ratio | 5.32-0.9 | 6.18+0.4 | 5.73+0.8 | 4.88-1.1 | 5.93+0.3 | 5.59+0.3 | 5.26-0.3 | 5.59 |
| Debt-to-Equity | 0.29+0.0 | 0.27-0.0 | 0.28-0.0 | 0.32+0.1 | 0.25-0.0 | 0.26-0.0 | 0.28+0.1 | 0.21 |
| FCF Margin | 17.9%+23.8pp | -5.9%+5.4pp | -11.3%-12.2pp | 0.9%+15.5pp | -14.6%-7.9pp | -6.7% | N/A | 13.9% |
Similar Companies
Frequently Asked Questions
What is Anika Therapeutics Inc's annual revenue?
Anika Therapeutics Inc (ANIK) reported $119.9M in total revenue for fiscal year 2024. This represents a -0.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Anika Therapeutics Inc's revenue growing?
Anika Therapeutics Inc (ANIK) revenue declined by 0.7% year-over-year, from $120.8M to $119.9M in fiscal year 2024.
Is Anika Therapeutics Inc profitable?
No, Anika Therapeutics Inc (ANIK) reported a net income of -$56.4M in fiscal year 2024, with a net profit margin of -47.0%.
What is Anika Therapeutics Inc's earnings per share (EPS)?
Anika Therapeutics Inc (ANIK) reported diluted earnings per share of $-3.83 for fiscal year 2024. This represents a 32.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Anika Therapeutics Inc's EBITDA?
Anika Therapeutics Inc (ANIK) had EBITDA of $1.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Anika Therapeutics Inc's gross margin?
Anika Therapeutics Inc (ANIK) had a gross margin of 63.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Anika Therapeutics Inc's operating margin?
Anika Therapeutics Inc (ANIK) had an operating margin of -4.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Anika Therapeutics Inc's net profit margin?
Anika Therapeutics Inc (ANIK) had a net profit margin of -47.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Anika Therapeutics Inc's free cash flow?
Anika Therapeutics Inc (ANIK) generated -$2.3M in free cash flow during fiscal year 2024. This represents a 67.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Anika Therapeutics Inc's operating cash flow?
Anika Therapeutics Inc (ANIK) generated $5.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Anika Therapeutics Inc's total assets?
Anika Therapeutics Inc (ANIK) had $202.7M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Anika Therapeutics Inc's capital expenditures?
Anika Therapeutics Inc (ANIK) invested $7.7M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Anika Therapeutics Inc spend on research and development?
Anika Therapeutics Inc (ANIK) invested $25.5M in research and development during fiscal year 2024.
Does Anika Therapeutics Inc buy back shares?
Yes, Anika Therapeutics Inc (ANIK) spent $10.9M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Anika Therapeutics Inc have outstanding?
Anika Therapeutics Inc (ANIK) had 14M shares outstanding as of fiscal year 2024.
What is Anika Therapeutics Inc's current ratio?
Anika Therapeutics Inc (ANIK) had a current ratio of 4.88 as of fiscal year 2024, which is generally considered healthy.
What is Anika Therapeutics Inc's debt-to-equity ratio?
Anika Therapeutics Inc (ANIK) had a debt-to-equity ratio of 0.32 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Anika Therapeutics Inc's return on assets (ROA)?
Anika Therapeutics Inc (ANIK) had a return on assets of -27.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Anika Therapeutics Inc's Piotroski F-Score?
Anika Therapeutics Inc (ANIK) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Anika Therapeutics Inc's earnings high quality?
Anika Therapeutics Inc (ANIK) has an earnings quality ratio of -0.10x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Anika Therapeutics Inc?
Anika Therapeutics Inc (ANIK) scores 45 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.